Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans

No abstract is available for this paper.

• Publication year

  2013

• Venue

  NeuroImage

• Publication date

  2013-07-15

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1016/j.neuroimage.2011.11.052PMID 22155032
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography

  2013cited by this paper
• In vivo evaluation of carbon-11-labelled non-sarcosine-based glycine transporter 1 inhibitors in mice and conscious monkeys.

  2011cited by this paper
• Glycine transporter-1: a new potential therapeutic target for schizophrenia.

  2011cited by this paper
• Biodistribution and Radiation Dosimetry of the Glycine Transporter-1 Ligand 11C-GSK931145 Determined from Primate and Human Whole-Body PET

  2011cited by this paper
• The synthesis and preclinical evaluation in rhesus monkey of [18F]MK‐6577 and [11C]CMPyPB glycine transporter 1 positron emission tomography radiotracers

  2011cited by this paper
• Radiosynthesis of [5-[ 11C]methanesulfonyl-2-((S)-2,2,2- trifluoro-1-methyl-ethoxy)-phenyl]-[5-(tetrahydro-pyran-4-yl)-1, 3-dihydro-isoindol-2-yl]-methanone ([ 11C]RO5013853), a novel PET tracer for the glycine transporter type i (GlyT1)

  2011influential reference
• Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1

  2011influential reference
• Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR

  2010cited by this paper
• Multi-graphical analysis of dynamic PET

  2010influential reference
• Linear Regression

  2010cited by this paper
• Pharmacological evaluation of a novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potential.

  2010influential reference
• Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.

  2010cited by this paper
• Identification and evaluation of [11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography

  2010cited by this paper
• Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.

  2009influential reference
• Positron emission tomography imaging.

  2009cited by this paper
• Evaluation of the novel glycine transporter 1 (GlyT1) tracer [18F]CFpyPB: Dosimetry and brain quantification in human

  2009influential reference
• A consistent and efficient graphical analysis method to improve the quantification of reversible tracer binding in radioligand receptor dynamic PET studies

  2009cited by this paper
• A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies.

  2008cited by this paper
• Blood levels and DA transporter occupancy of orally administered methylphenidate in juvenile rhesus monkeys measured by high resolution PET

  2008cited by this paper
• [11C]GSK931145: A new pet ligand for glycine transporter 1

  2008influential reference
• Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease

  2007influential reference
• CHAPTER 2 – Statistical parametric mapping

  2007cited by this paper
• Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands

  2007influential reference
• 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors.

  2006cited by this paper
• Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies

  2006influential reference
• A CHARACTERIZATION OF FIBRANT SEGAL CATEGORIES

  2006cited by this paper
• OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

  2005cited by this paper
• Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

  2005cited by this paper
• Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain.

  2005cited by this paper
• N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives

  2005cited by this paper
• Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

  2005cited by this paper
• Statistical list-mode image reconstruction for the high resolution research tomograph

  2004cited by this paper
• Identification and interpretation of microparameters in neuroreceptor compartmental models

  2004influential reference
• The search for novel antipsychotics: pharmacological and molecular targets

  2004cited by this paper
• Statistical list-mode image reconstruction for the high resolution research tomograph.

  2004influential reference
• PHYSICAL MODELS AND DOSE FACTORS FOR USE IN INTERNAL DOSE ASSESSMENT

  2003cited by this paper
• Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model

  2003cited by this paper
• On the Undecidability among Kinetic Models: From Model Selection to Model Averaging

  2003influential reference
• Kinetic modeling in positron emission tomography.

  2002influential reference
• Positron Emission Tomography Compartmental Models

  2001cited by this paper
• Column-switching HPLC for the analysis of plasma in PET imaging studies.

  2000cited by this paper
• Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion

  1997cited by this paper
• Simplified reference tissue model for PET receptor studies.

  1996cited by this paper
• Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652

  1995cited by this paper
• Regional Distribution and Developmental Variation of the Glycine Transporters GLYT1 and GLYT2 in the Rat CNS

  1995cited by this paper
• Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

  1994cited by this paper
• In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428

  1993cited by this paper
• Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography

  1991influential reference
• Therapeutic factors in partial hospitalization.

  1988cited by this paper
• Neuroreceptor Assay with Positron Emission Tomography: Equilibrium versus Dynamic Approaches

  1986cited by this paper
• Imaging Opiate Receptors in the Human Brain by Positron Tomography

  1985cited by this paper
• Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations

  1985cited by this paper
• Imaging dopamine receptors in the human brain by positron tomography.

  1984cited by this paper
• EFFECTS OF AGE ON DOPAMINE AND SEROTONIN RECEPTORS MEASURED BY POSITRON TOMOGRAPHY IN THE LIVING HUMAN BRAIN

  1984cited by this paper
• Imaging dopamine receptors in the human brain by positron tomography

  1983cited by this paper
• Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data

  1983cited by this paper
• High‐ and Low‐Affinity Transport of D‐Glucose from Blood to Brain

  1981cited by this paper
• Evaluation of Novel

  year unknowncited by this paper
• Journal of Cerebral Blood Flow and Metabolism Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to E8p]cyclofoxy and Positron Emission Tomography Cyclofoxy Infusion for Opiate Receptor Quant/tat/on Theory Compartment Models for Receptor-binding Radiotracers

  year unknowninfluential reference

• Therapeutic potential of D-amino acid oxidase inhibitors for cognitive impairment associated with schizophrenia: learnings from luvadaxistat

  2025cites this paper
• The "five-star matrix" for patient-centric drug discovery and development in neuroscience.

  2025cites this paper
• [3H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain

  2024cites this paper
• Neuroimaging biomarkers for drug discovery and development in Schizophrenia.

  2024cites this paper
• Azetidine-based selective glycine transporter-1 (GlyT1) inhibitors with memory enhancing properties.

  2020cites this paper
• Brain PET Imaging of α7-nAChR with [18F]ASEM: Reproducibility, Occupancy, Receptor Density, and Changes in Schizophrenia

  2018cites this paper
• Glycine transporter-1 inhibitors: a patent review (2011–2016)

  2018cites this paper
• PET Brain imaging of α7-nAChR with [18F]ASEM

  2018cites this paper
• Molecular imaging of autism spectrum disorder

  2017cites this paper
• Small Molecule PET Tracers for Transporter Imaging.

  2017cites this paper
• PET in Neurological and Psychiatric Disorders: Technologic Advances and Clinical Applications

  2017cites this paper
• Progress and Challenges in the Development of PET Ligands to Aid CNS Drug Discovery

  2017cites this paper
• Inhibitors of Glycine Transporter-1: Potential Therapeutics for the Treatment of CNS Disorders.

  2016cites this paper
• Comparative evaluation of two glycine transporter 1 radiotracers [11C]GSK931145 and [18F]MK‐6577 in baboons

  2016influential citation
• Medicinal Chemists Don't Just Make Drugs - The Art of Developing Low Molecular Weight Imaging Agents in Switzerland.

  2016cites this paper
• Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?

  2015cites this paper
• Quantitative imaging of protein targets in the human brain with PET

  2015cites this paper
• Measurement of Bmax and Kd with the Glycine Transporter 1 Radiotracer 18F-MK6577 using a Novel Multi-Infusion Paradigm

  2015cites this paper
• Characterization of the novel GlyT1 PET tracer [18F]MK‐6577 in humans

  2015cites this paper
• Translating the Glutamatergic Hypothesis of Schizophrenia Through Homeostatic Regulation of Brain Glycine

  2015cites this paper
• Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

  2014cites this paper
• Imaging Type I Glycine Transporters in the CNS using Positron Emission Tomography

  2014cites this paper
• Relationship Between Glycine Transporter 1 Inhibition as Measured with Positron Emission Tomography and Changes in Cognitive Performances in Nonhuman Primates

  2014cites this paper
• GlyT-1 Inhibitors: From Hits to Clinical Candidates

  2014cites this paper
• Modulation of NMDA receptor function as a treatment for schizophrenia.

  2013cites this paper
• Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers

  2013cites this paper
• Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography

  2013cites this paper
• Molecular imaging as a guide for the treatment of central nervous system disorders

  2013cites this paper
• The glycine deportation system and its pharmacological consequences.

  2012cites this paper